The BTK Inhibitor Ibrutinib (PCI-32765) Overcomes Paclitaxel Resistance in ABCB1- and ABCC10-Overexpressing Cells and Tumors

Paclitaxel is one of the most widely used antineoplastic drugs in the clinic. Unfortunately, the occurrence of cellular resistance has limited its efficacy and application. The ATP-binding cassette subfamily B member 1 (ABCB1/P-glycoprotein) and subfamily C member 10 (ABCC10/MRP7) are the major memb...

Full description

Saved in:
Bibliographic Details
Published in:Mol Cancer Ther
Main Authors: Zhang, Hui, Patel, Atish, Wang, Yi-Jun, Zhang, Yun-Kai, Kathawala, Rishil J., Qiu, Long-Hui, Patel, Bhargav A., Huang, Li-Hua, Shukla, Suneet, Yang, Dong-Hua, Ambudkar, Suresh V., Fu, Li-Wu, Chen, Zhe-Sheng
Format: Artigo
Language:Inglês
Published: 2017
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7830771/
https://ncbi.nlm.nih.gov/pubmed/28265007
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-16-0511
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items